Ninlaro (ixazomib) is a small molecule pharmaceutical. Ixazomib was first approved as Ninlaro on 2015-11-20. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. The pharmaceutical is active against proteasome subunit beta type-5. In addition, it is known to target proteasome subunit alpha type-7. Ninlaro's patents are valid until 2029-11-20 (FDA).
|Drug Class||Proteozome inhibitors|